Please assess the completion status of the following clinical trial:

Trial Title: Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Clinically diagnosed E. coli-associated diarrhea-associated hemolytic uremic syndrome (HUS)~* Diarrheal prodrome within 7 days before onset of disease~* No HUS associated with the following: Hereditary Post-bone marrow transplantation Streptococcus pneumoniae infection~* No prior catastrophic complications~--Patient Characteristics--~* Hematopoietic: Thrombocytopenia less than 140,000/mm3 Fragmented red blood cells~* Renal: Renal involvement (hematuria, proteinuria, or azotemia) No underlying glomerular disease~* Other: HIV negative No pre-existing structural abnormality or dysmotility syndrome of the gastrointestinal tract No inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- SYNSORB Pk (Type: EXPERIMENTAL): Oral Shiga toxin-binding agent (500 mg/kg/day)
- Placebo (Type: PLACEBO_COMPARATOR): Cornmeal placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).